(BUSINESS WIRE)–Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix” or the “Company”) today announced the promotion of William P. Forbes, PharmD to President, Medical, Research and Development and Chief Development Officer. Read more »
Shares of Salix Pharmaceuticals closed last Friday at $134.67 . SLXP has a 1-year high of $172.98 and a 1-year low of $86. The stock’s 50-day moving average is $119.76 and it’s 200-day moving average is $131.32.
On the ratings front, Salix Pharmaceuticals (NASDAQ:SLXP) has been the subject of a number of recent research reports. In a report issued on January 29, Cantor Fitzgerald analyst Irina Rivkind maintained a Buy rating on SLXP, with a price target of $151, which reflects a potential upside of 12.1% from last closing price. Separately, on the same day, UBS’s Marc Goodman reiterated a Buy rating on the stock and has a price target of $144.
In total, 6 research analysts have assigned a Hold rating and 8 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $134.67 which is -5.4% under where the stock closed last Friday.
Salix Pharmaceuticals Ltd is a specialty pharmaceutical company, which is dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases.